Literature DB >> 12217605

Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners.

Jim E van Steenbergen1.   

Abstract

BACKGROUND/AIMS: The Dutch Ministry of Health funded a pilot vaccination project targeting groups at high risk for sex- and drug-related hepatitis B transmission.
METHODS: In seven Municipal Health Service (MHS) areas, three-part hepatitis B vaccination was offered free to men who have sex with men (MSM), drug users (DUs), and heterosexuals with multiple partners, including sex workers (SWs). Four intervention areas recruited participants through care-givers and opinion leaders and offered vaccination at non-MHS sites. Three control areas only used flyers to offer vaccination at MHS during regular hours.
RESULTS: Over 18 months, 13808 persons enrolled for the first vaccination, representing 63% of the targeted population in the intervention areas and 23% in control areas. In intervention areas, only 19% of DUs enrolled, versus 4% in control areas. In both areas, enrollment of the targeted heterosexual population (64%) was satisfactory. MSM were most compliant in having the full series. Of vaccination sources, general practitioners (GPs) attained highest compliance (71%, odds ratio 1.82).
CONCLUSIONS: Dutch MHS facilities can reach high-risk individuals, but DUs require additional outreach. Vaccine coverage was disappointing, but our experience will be deployed nationwide and successful strategies might be employed elsewhere in countries of low endemicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217605     DOI: 10.1016/s0168-8278(02)00213-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

Review 1.  Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance.

Authors:  K Van Herck; E Leuridan; P Van Damme
Journal:  Sex Transm Infect       Date:  2007-10       Impact factor: 3.519

Review 2.  Should universal hepatitis B immunisation be introduced in the UK?

Authors:  P English
Journal:  Arch Dis Child       Date:  2006-04       Impact factor: 3.791

3.  Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial.

Authors:  Lu-Yu Hwang; Carolyn Z Grimes; Thanh Quoc Tran; April Clark; Rui Xia; Dejian Lai; Catherine Troisi; Mark Williams
Journal:  J Infect Dis       Date:  2010-10-11       Impact factor: 5.226

4.  Adherence to hepatitis B virus vaccination at syringe exchange sites.

Authors:  Frederick L Altice; Robert D Bruce; Mary R Walton; Marta I Buitrago
Journal:  J Urban Health       Date:  2005-03-03       Impact factor: 3.671

Review 5.  Systematic review of the incremental costs of interventions that increase immunization coverage.

Authors:  Sachiko Ozawa; Tatenda T Yemeke; Kimberly M Thompson
Journal:  Vaccine       Date:  2018-05-10       Impact factor: 3.641

Review 6.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Hepatitis A Virus among Drug Users and the Role of Vaccination: A Review.

Authors:  Fabio Lugoboni; Benedetta Pajusco; Anna Albiero; Gianluca Quaglio
Journal:  Front Psychiatry       Date:  2012-01-12       Impact factor: 4.157

Review 8.  Bloodborne viral hepatitis infections among drug users: the role of vaccination.

Authors:  Fabio Lugoboni; Gianluca Quaglio; Paolo Civitelli; Paolo Mezzelani
Journal:  Int J Environ Res Public Health       Date:  2009-01-22       Impact factor: 3.390

9.  Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands.

Authors:  Susan Hahné; Robin van Houdt; Femke Koedijk; Marijn van Ballegooijen; Jeroen Cremer; Sylvia Bruisten; Roel Coutinho; Hein Boot
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.